- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
Why Shares of Zogenix Fell 26% in September презентация
Содержание
What happened? Biotech stocks were sold off in September, as the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) fell 9% during the month.
Слайд 2What happened?
Biotech stocks were sold off in September, as the iShares
Nasdaq Biotechnology ETF (NASDAQ: IBB) fell 9% during the month.
Слайд 3What happened?
Shares of Zogenix (NASDAQ: ZGNX) were sold off even harder,
despite releasing good clinical news.
Слайд 4So What?
Top-line data from a phase 1b trial of Relday, the
company’s experimental once a month Schizophrenia medication, was released in September.
Results look good enough to start phase 3 testing, but the company is holding off until it finds a partner, which may be the reason that investors dumped the shares.
The company estimates trials will begin in Q1 2016.
Peak sales are estimated to be around $250 million annually.
Results look good enough to start phase 3 testing, but the company is holding off until it finds a partner, which may be the reason that investors dumped the shares.
The company estimates trials will begin in Q1 2016.
Peak sales are estimated to be around $250 million annually.
Слайд 5Now what?
Beyond Relday, the company’s lead compound, ZX008, is being studied
as a treatment for Dravet Syndrome, which is an orphan disease that causes seizures that do not respond to standard treatments.
ZX008 has received orphan drug designation in the U.S. & Europe, and peak sales estimates are around $200 million.
Phase 3 studies for ZX008 should start in the fourth quarter of 2015.
The company raised $98 million in an August common stock offering, so it appears to be well capitalized.
Zogenix remains very speculative, so I’m content to stay away until we see good phase 3 data for either ZX008 or Relday.
ZX008 has received orphan drug designation in the U.S. & Europe, and peak sales estimates are around $200 million.
Phase 3 studies for ZX008 should start in the fourth quarter of 2015.
The company raised $98 million in an August common stock offering, so it appears to be well capitalized.
Zogenix remains very speculative, so I’m content to stay away until we see good phase 3 data for either ZX008 or Relday.
